SBIR Phase I: Detection of Chronic Diseases via Multiplex Analysis of Circulating Metabolites

小型企业创新研究(SBIR)第一阶段项目的更广泛影响/商业潜力是一种新的代谢物诊断血液测试，可指示早期疾病，包括癌症、慢性心肺疾病和糖尿病。这项技术分析了血液代谢产物的特定面板，这些面板指示了疾病发生的细胞功能变化。这项技术将诊断间隔时间从几年减少到几周或几天，减少了因治疗不当而导致的误诊，并有可能将更具侵入性的诊断方法(如活检、结肠镜检查和心脏插管)的使用从探索性角色改变为确认性角色。这个小型企业创新研究(SBIR)第一阶段项目旨在使用特定的循环代谢物面板，使用质谱仪(MS)测量并使用人工智能进行分析，以检测慢性疾病情况。临床前模型已经证明，代谢变化发生在轻度疾病阶段，在显性症状变得明显之前。在这个项目中要评估的第一个具体情况是肺动脉高压。其目的是根据临床使用的需要，以可重复性的方式建立具有多重代谢物面板的量化值的校准的MS方法。还将开发多标签分类，以检测和解释可能影响整体新陈代谢变化的各种并存疾病。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel metabolite diagnostic blood test indicative of early-stage diseases including cancer, chronic heart and lung disorders, and diabetes. The technology analyzes specific panels of blood metabolites indicative of changes in cellular function that occur with disease. This technology reduces the diagnostic interval time from years to weeks or days, diminishes misdiagnosis resulting in improper therapy, and has the potential to alter the use of more invasive diagnostic methods such as biopsies, colonoscopies, and heart catheterizations from an exploratory to a confirmatory role. This Small Business Innovation Research (SBIR) Phase I project aims to use specific panels of circulating metabolites measured using mass spectrometry (MS) and analyzed using artificial intelligence to detect chronic disease conditions. Pre-clinical models have demonstrated that alterations in metabolism occur at the stage of mild disease, before overt symptoms become evident. The first specific condition to be evaluated in this project is pulmonary arterial hypertension. The objective is to establish calibrated MS methods with quantified values of multiplexed metabolite panels in a reproducible manner as required for clinical use. Multi-label classifications will also be developed in order to detect and account for various co-morbidities that can affect overall metabolic changes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.